StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Stock analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Down 3.6 %

Cyclacel Pharmaceuticals stock opened at $0.32 on Friday. The firm has a market capitalization of $2.00 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. The firm’s fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.60. Cyclacel Pharmaceuticals has a 1-year low of $0.30 and a 1-year high of $4.00.

Insider Transactions at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.